Answer
| Feature | Ampoule | Vial |
|---|---|---|
| Material | Glass only | Glass or plastic |
| Opening | Break the neck | Needle through rubber stopper |
| Doses | Single-dose only | Single or multi-dose |
| Preservative | Usually none | Present in multi-dose vials |
| Glass particle risk | Yes | No |
| Re-entry possible | No | Yes (vials) |
| Filter needle needed | Yes (recommended) | Not routinely |
| Cost | Lower | Higher |
Answer
| Alkaloid | Class | Clinical Use |
|---|---|---|
| Morphine (10–15%) | Phenanthrene | Analgesia, acute pulmonary edema |
| Codeine (1–3%) | Phenanthrene | Mild-moderate pain, antitussive |
| Thebaine (~0.2%) | Phenanthrene | Precursor for oxycodone, naloxone, buprenorphine |
| Papaverine (~1%) | Benzylisoquinoline | Smooth muscle relaxant, vasospasm |
| Noscapine (~6%) | Benzylisoquinoline | Antitussive |
Raw Opium Latex
│
├── Morphine ──────→ Heroin (diacetylmorphine)
│ → Hydromorphone
│
├── Codeine ───────→ Dihydrocodeine
│
└── Thebaine ──────→ Oxycodone
→ Buprenorphine
→ Naloxone / Naltrexone
→ Etorphine
Answers
5 mcg/kg/min × 60 kg = 300 mcg/min
Dose needed = 300 mcg/minVolume/min = 300 mcg/min ÷ 40,000 mcg/mL = 0.0075 mL/min
Total volume = 505 mL ≈ 500 mL Concentration = 200 mg / 500 mL = 0.4 mg/mL = 400 mcg/mL
Dose = 300 mcg/minRate = 300 mcg/min ÷ 400 mcg/mL = 0.75 mL/min = 45 mL/hour
0.75 mL/min × 20 drops/mL = 15 drops/min
| Issue | Problem | Correction |
|---|---|---|
| Metronidazole dose (①②) | 100 mg & 200 mg doses are sub-therapeutic for amoebic dysentery | Correct adult dose: 800 mg TDS (3× daily) × 5–10 days |
| Two metronidazole entries | Duplicated/conflicting prescriptions | Use one entry only |
| Furazolidone | Not indicated as first-line for amoebic dysentery; active against bacteria/Giardia | Can be used for Giardia but not amoeba — remove or replace |
| Alcohol interaction | Metronidazole causes a disulfiram-like reaction with alcohol | Counsel the patient strictly: NO alcohol during and 48 hrs after treatment |
1. Tab. Metronidazole 800 mg — TDS × 7 days
(With food; avoid alcohol completely)
2. Tab. Diloxanide furoate 500 mg — TDS × 10 days
(Luminal agent to eradicate cysts after metronidazole)
CAUTION: Patient is alcoholic — warn about
disulfiram-like reaction with metronidazole.
Metronidazole kills trophozoites (tissue amoeba). Diloxanide furoate eliminates luminal cysts to prevent relapse — the two together constitute complete treatment of amoebic dysentery.
Experiment on frog isolated heart
| Parameter | Effect |
|---|---|
| Rate | ↑ (positive chronotropy) |
| Force | ↑ (positive inotropy) |
| Mechanism | β₁ receptor → ↑ cAMP → ↑ Ca²⁺ influx |
| Tracing | Taller, more frequent waves |
| Parameter | Effect |
|---|---|
| Rate | ↓ (negative chronotropy) |
| Force | ↓ (negative inotropy) |
| Mechanism | M₂ receptor → ↑ K⁺ efflux → hyperpolarization |
| Tracing | Smaller, slower waves; may cause cardiac arrest in diastole |
| Result |
|---|
| Atropine alone: slight ↑ rate (vagal block) |
| Atropine blocks ACh effects completely |
| Tracing: ACh has no effect after atropine pretreatment |
Demonstrates competitive antagonism
| Parameter | Effect |
|---|---|
| Rate | ↓↓ |
| Mechanism | Depolarizes the resting membrane → reduces excitability |
| Tracing | Slower, weaker beats → cardiac arrest in diastole (hyperkalemia) |
| Parameter | Effect |
|---|---|
| Force | ↑↑ |
| Rate | ↓ |
| Mechanism | ↑ intracellular Ca²⁺ → stronger contraction |
| Tracing | Taller beats, slower rate → cardiac arrest in systole (hypercalcemia) |
| Parameter | Effect |
|---|---|
| Force | ↑ (positive inotropy) |
| Rate | ↓ (negative chronotropy) |
| Mechanism | Inhibits Na⁺/K⁺-ATPase → ↑ intracellular Na⁺ → ↑ Ca²⁺ via Na/Ca exchanger |
| Tracing | Stronger, slower, more regular beats |
| Ligature | Position | Effect |
|---|---|---|
| 1st Stannius | Between sinus venosus & right atrium | Atria & ventricle stop; sinus continues |
| 2nd Stannius | AV groove (between atria & ventricle) | Ventricle starts beating at its own slower rate |
Proves: Sinus venosus (= SA node equivalent) is the primary pacemaker
| Drug | Rate | Amplitude | Rhythm | Arrest |
|---|---|---|---|---|
| Adrenaline | ↑ | ↑ | Regular | None |
| Acetylcholine | ↓ | ↓ | Regular→slow | Diastole |
| Atropine + ACh | Normal | Normal | Regular | None |
| Excess KCl | ↓↓ | ↓↓ | Irregular | Diastole |
| Excess CaCl₂ | ↓ | ↑↑ | Regular | Systole |
| Digitalis | ↓ | ↑ | Regular | None (therapeutic) |
Write about essential drugs
"Those that satisfy the priority health care needs of the population. They are selected with due regard to disease prevalence, evidence on efficacy and safety, and comparative cost-effectiveness."
| Criterion | Details |
|---|---|
| Relevance | Must address prevalent diseases in the community |
| Efficacy | Proven by adequate clinical evidence (RCTs, meta-analyses) |
| Safety | Acceptable risk-benefit ratio |
| Quality | Pharmaceutical quality, stability, bioavailability assured |
| Cost-effectiveness | Affordable; best outcome per cost |
| Availability | Can be supplied in adequate quantities |
| Drug | Use |
|---|---|
| Aspirin | Mild pain, fever, antiplatelet |
| Paracetamol (Acetaminophen) | Pain, fever (safest for all ages) |
| Ibuprofen | Pain, fever, inflammation |
| Morphine | Severe pain, cancer pain |
| Codeine | Moderate pain, cough |
| Drug | Use |
|---|---|
| Amoxicillin | Respiratory, ENT infections |
| Ampicillin | Gram-positive/negative infections |
| Benzylpenicillin | Streptococcal, meningococcal infections |
| Ciprofloxacin | UTI, GI infections, anthrax |
| Metronidazole | Anaerobes, amoeba, Giardia, BV |
| Cotrimoxazole | PCP, UTI, Pneumocystis in HIV |
| Doxycycline | Malaria, chlamydia, rickettsia |
| Gentamicin | Gram-negative sepsis (IV) |
| Chloramphenicol | Meningitis, typhoid (reserve) |
| Drug | Use |
|---|---|
| Artemether + Lumefantrine | First-line uncomplicated malaria |
| Artesunate (IV) | Severe/complicated malaria |
| Chloroquine | P. vivax, P. ovale |
| Primaquine | Radical cure of P. vivax (liver stage) |
| Quinine | Severe malaria (reserve) |
| Drug | Abbreviation |
|---|---|
| Isoniazid | H |
| Rifampicin | R |
| Pyrazinamide | Z |
| Ethambutol | E |
| Streptomycin | S |
Standard regimen: 2HRZE / 4HR
| Class | Examples |
|---|---|
| NRTIs | Zidovudine, Tenofovir, Lamivudine |
| NNRTIs | Efavirenz, Nevirapine |
| PIs | Lopinavir/ritonavir |
| Integrase inhibitors | Dolutegravir (preferred 1st line) |
| Drug | Use |
|---|---|
| Atenolol / Metoprolol | Hypertension, angina, MI |
| Amlodipine | Hypertension, angina |
| Enalapril / Lisinopril | Hypertension, heart failure |
| Hydrochlorothiazide | Hypertension, edema |
| Digoxin | Heart failure, AF rate control |
| Dopamine | Cardiogenic shock |
| Adrenaline (Epinephrine) | Anaphylaxis, cardiac arrest |
| Streptokinase / Alteplase | Thrombolysis in MI, stroke |
| Aspirin | Antiplatelet in ACS |
| Drug | Use |
|---|---|
| Salbutamol (Albuterol) | Acute bronchospasm (SABA) |
| Beclomethasone (inhaled) | Asthma prophylaxis (ICS) |
| Aminophylline | Severe asthma, COPD |
| Ipratropium | COPD bronchodilator |
| Drug | Use |
|---|---|
| Omeprazole | PUD, GERD, H. pylori |
| Ranitidine | Peptic ulcer (H₂ blocker) |
| Antacids (Mg/Al hydroxide) | Heartburn, dyspepsia |
| ORS (Oral Rehydration Salts) | Diarrhea, dehydration |
| Metoclopramide | Nausea, vomiting |
| Lactulose | Constipation, hepatic encephalopathy |
| Drug | Use |
|---|---|
| Metformin | Type 2 DM (first line) |
| Insulin (regular, NPH) | Type 1 DM, severe Type 2 DM |
| Glibenclamide (Glyburide) | Type 2 DM (sulfonylurea) |
| Vaccine | Disease |
|---|---|
| BCG | Tuberculosis |
| OPV / IPV | Poliomyelitis |
| DTP | Diphtheria, Tetanus, Pertussis |
| MMR | Measles, Mumps, Rubella |
| Hepatitis B vaccine | Hepatitis B |
| Pneumococcal vaccine | Pneumococcal pneumonia |
| Drug | Use |
|---|---|
| Oxytocin | Labour induction, PPH |
| Ergometrine | PPH (uterotonic) |
| Misoprostol | PPH, cervical ripening, abortion |
| Magnesium sulfate | Eclampsia, pre-eclampsia |
| Contraceptives (levonorgestrel, DMPA) | Family planning |
| Drug | Use |
|---|---|
| Ketamine | Dissociative anaesthesia |
| Halothane / Isoflurane | General anaesthesia (inhalation) |
| Thiopentone | IV induction |
| Lignocaine (Lidocaine) | Local anaesthesia, arrhythmia |
| Atropine | Pre-anaesthetic medication; bradycardia |
| Morphine | Pre-medication, post-op analgesia |
| Neostigmine | Reversal of neuromuscular blockade |
| Drug | Use |
|---|---|
| Phenobarbitone | Generalized seizures |
| Phenytoin | Tonic-clonic seizures |
| Carbamazepine | Partial, tonic-clonic seizures |
| Diazepam | Status epilepticus (IV/rectal) |
| Sodium valproate | Broad-spectrum antiepileptic |
| Drug | Use |
|---|---|
| Prednisolone | Inflammation, autoimmune disease |
| Dexamethasone | Cerebral edema, croup, anaphylaxis |
| Hydrocortisone | Adrenal crisis, acute allergy |
| Betamethasone | Fetal lung maturity (antenatal) |
| Antidote | Poison/Drug |
|---|---|
| Naloxone | Opioid overdose |
| Flumazenil | Benzodiazepine overdose |
| Atropine | Organophosphate poisoning |
| Pralidoxime (2-PAM) | Organophosphate (reactivates AChE) |
| Desferrioxamine | Iron poisoning |
| N-acetylcysteine | Paracetamol overdose |
| Activated charcoal | General poisoning (within 1 hr) |
| Dimercaprol (BAL) | Lead, arsenic, mercury |
| Country | List Name |
|---|---|
| India | National List of Essential Medicines (NLEM) — 2022: 384 drugs |
| UK | BNF Formulary |
| USA | Formulary-based systems |
| WHO | Model List — ~500 medicines |
Right drug — Right dose — Right route — Right duration — Right patient — Right cost
| Fact | Detail |
|---|---|
| WHO first list | 1977 |
| Current WHO list | 23rd edition, 2023 |
| Number of medicines | ~500 |
| India NLEM 2022 | 384 drugs |
| Basis of selection | Efficacy, safety, cost-effectiveness, disease burden |
| Goal | Universal access to safe, effective, quality medicines |
| Concept introduced by | WHO — Dr. Ernst Lauridsen (1975 concept), 1977 list |